Crossmark

Feasibility and safety of low-flow extracorporeal CO2 removal managed with a renal replacement platform to enhance lung-protective ventilation of patients with mild-to-moderate ARDS

Crossref DOI link: https://doi.org/10.1186/s13054-018-2038-5

Published Online: 2018-05-10

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schmidt, Matthieu

Jaber, Samir

Zogheib, Elie

Godet, Thomas

Capellier, Gilles

Combes, Alain https://orcid.org/0000-0002-6030-3957
Funding

Funding for this research was provided by:

Baxter Healthcare Corporation
License Information

Text and Data Mining valid from 2018-05-10
More Information

Article History

Received: 30 November 2017

Accepted: 13 April 2018

First Online: 10 May 2018

Ethics approval and consent to participate

: The study was approved by the Comité de Protection des Personnes Ile-de-France 6, Paris, France (no. 15.1026). The clinical trial protocol was registered with (ClinicalTrials.gov identifier: NCT02606240, 17 November 2015). Informed consent was obtained from all patients or their surrogates.

: MS has received lecture fees from Maquet. SJ has received lecture fees from Drager, Fisher-Paykel, and Xenios. EZ has received consultant fees from Gambro. TG has received lecture fees and travel reimbursements for meetings from Gambro-Baxter and General Electrics. GC has received lecture fees from Alung and Baxter. AC has received lecture fees from Baxter and Maquet. AC is the primary investigator of the EOLIA trial (ClinicalTrials.gov identifier: NCT01470703), partly supported by Maquet.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below